

# Deborah M Siegal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9003231/publications.pdf>

Version: 2024-02-01

110  
papers

8,554  
citations

101543

36  
h-index

45317

90  
g-index

110  
all docs

110  
docs citations

110  
times ranked

8407  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 830-841.	3.4	10
2	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. <i>Blood Advances</i> , 2022, 6, 664-671.	5.2	53
3	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	7.4	89
4	Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study. <i>Leukemia Research</i> , 2022, 113, 106788.	0.8	0
5	Perceptions of patients and healthcare providers on patient education to improve oral anticoagulant management. <i>Journal of Evaluation in Clinical Practice</i> , 2022, 28, 1027-1036.	1.8	4
6	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	5.2	42
7	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. <i>Blood Reviews</i> , 2022, 56, 100970.	5.7	12
8	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1910-1919.	3.8	12
9	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
10	Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study. <i>BMJ Open</i> , 2022, 12, e057991.	1.9	1
11	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	5.2	21
12	Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12747.	2.3	4
13	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	3.8	31
14	Thinking Outside the Inbox: Use of Slack in Clinical Groups as a Collaborative Team Communication Platform. <i>AEM Education and Training</i> , 2021, 5, 121-129.	1.2	10
15	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	3.4	29
16	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	3.4	8
17	Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of healthcare providers. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 153-160.	3.8	12
18	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 30-40.	3.8	8

#	ARTICLE	IF	CITATIONS
19	Ciraparantag: the next anticoagulant airbag?. <i>Blood</i> , 2021, 137, 10-11.	1.4	1
20	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. <i>Cmaj</i> , 2021, 193, E304-E309.	2.0	13
21	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	3.4	14
22	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 872-888.	5.2	310
23	Considerations for use of direct oral anticoagulants in arterial disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12502.	2.3	1
24	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM&Line): A two&center open&label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12517.	2.3	8
25	Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey. <i>Thrombosis Research</i> , 2021, 201, 30-49.	1.7	3
26	Anticoagulant&associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2383-2393.	3.8	19
27	Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and meta&analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2504-2513.	3.8	9
28	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	27.0	778
29	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	27.0	712
30	Incidence of stroke in the first year after diagnosis of cancer&A protocol for systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0256825.	2.5	3
31	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021, 5, 3951-3959.	5.2	49
32	Barriers and facilitators for optimizing oral anticoagulant management: Perspectives of patients, caregivers, and providers. <i>PLoS ONE</i> , 2021, 16, e0257798.	2.5	8
33	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021, 206, 52-54.	1.7	0
34	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. <i>Blood</i> , 2021, 138, 175-175.	1.4	0
35	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1074-1079.	2.8	17
36	Shared Decision-Making for Anticoagulation in Atrial Fibrillation: Do Physicians Really Listen?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 459-461.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. <i>Heart</i> , 2020, 106, 845-851.	2.9	3
38	Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. <i>Transfusion</i> , 2020, 60, 256-261.	1.6	23
39	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	2.8	187
40	Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 677-679.	2.3	4
41	Narrowing in on the True Rate of Venous Thromboembolism in Hospitalized Patients With COVID-19 Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1958-1960.	2.4	1
42	Iron deficiency following bariatric surgery: a retrospective cohort study. <i>Blood Advances</i> , 2020, 4, 3639-3647.	5.2	23
43	Intravenous iron therapy for patients with preoperative iron deficiency or anaemia undergoing cardiac surgery reduces blood transfusions: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 141-151.	1.1	14
44	The Use of Transthoracic Echocardiograms in Hospitalized Adult Patients with Acute Pulmonary Embolism. <i>Blood</i> , 2020, 136, 43-43.	1.4	1
45	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. <i>Blood Advances</i> , 2020, 4, 6259-6273.	5.2	7
46	Characterizing Frailty in Myeloproliferative Neoplasms: Baseline Results from the Orchid Study. <i>Blood</i> , 2020, 136, 9-10.	1.4	1
47	Detection of Right Ventricular Dysfunction in Acute Pulmonary Embolism By CT Scan: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2020, 136, 25-26.	1.4	0
48	Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. <i>Lancet</i> , 2019, 394, 1022-1029.	13.7	146
49	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1966-1972.	3.8	70
50	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227) Study. <i>Chest</i> , 2019, 155, 793-801.	2.7	12
51	Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. <i>Circulation</i> , 2019, 139, 757-759.	1.6	3
52	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding. <i>Thrombosis Research</i> , 2019, 180, 86.	1.7	0
53	Refractory urticaria and the importance of diagnosing Schnitzler's syndrome. <i>BMJ Case Reports</i> , 2019, 12, e228546.	0.5	3
54	Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 179, 81-86.	1.7	47

#	ARTICLE	IF	CITATIONS
55	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
56	Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 204-208.	2.5	3
57	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019, 15, 395-404.	1.2	5
58	The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, S332-S333.	0.4	4
59	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section 3 Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	3.4	28
60	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 175, 102-109.	1.7	49
61	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. <i>Blood</i> , 2019, 134, 3685-3685.	1.4	8
62	What we have learned about direct oral anticoagulant reversal. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 198-203.	2.5	11
63	Pharmacological reversal of the direct oral anticoagulants: A comprehensive review of the literature. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 251-265.	2.3	35
64	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018, 163, 19-21.	1.7	6
65	Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. <i>Thrombosis Research</i> , 2018, 167, 6-8.	1.7	1
66	2. Abstract Title: Risk of venous and arterial thrombosis in patients receiving tranexamic acid: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2018, 170, 2.	1.7	0
67	Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2008-2015.	3.8	15
68	The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. <i>Leukemia Research</i> , 2018, 70, 62-66.	0.8	4
69	Blood Loss Due to Laboratory Testing in Critical Care Patients: A Retrospective Cohort Study. <i>Blood</i> , 2018, 132, 4885-4885.	1.4	0
70	Small-Volume Tubes to Reduce Transfusion (STRATUS): A Pilot Study. <i>Blood</i> , 2018, 132, 825-825.	1.4	9
71	Specific antidotes for bleeding associated with direct oral anticoagulants. <i>BMJ: British Medical Journal</i> , 2017, 357, j2216.	2.3	15
72	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017, 157, 165-166.	1.7	9

#	ARTICLE	IF	CITATIONS
73	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	2.8	285
74	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	1.7	18
75	Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia. <i>Annals of Internal Medicine</i> , 2017, 167, 170.	3.9	42
76	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.8	245
77	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. <i>Blood Advances</i> , 2017, 1, 772-778.	5.2	82
78	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	5.2	50
79	Occult Amebic Liver Abscess as Cause of Extensive Inferior Vena Cava and Hepatic Vein Thrombosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1214-1217.	1.4	9
80	The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. <i>Blood</i> , 2016, 128, 138-140.	1.4	190
81	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	27.0	692
82	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 879-890.	3.4	139
83	Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 448-453.	2.5	6
84	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	50
85	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 395-402.	2.1	66
86	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	2.1	32
87	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015, 373, 2413-2424.	27.0	907
88	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	12
89	Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review. <i>Blood</i> , 2015, 126, 1137-1137.	1.4	1
90	Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery. <i>Blood</i> , 2015, 126, 1130-1130.	1.4	1

#	ARTICLE	IF	CITATIONS
91	What is the effect of rivaroxaban on routine coagulation tests?. Hematology American Society of Hematology Education Program, 2014, 2014, 334-336.	2.5	7
92	Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants. Journal of the American College of Cardiology, 2014, 64, 1128-1139.	2.8	414
93	Reversal of target-specific oral anticoagulants. Drug Discovery Today, 2014, 19, 1465-1470.	6.4	32
94	How I treat target-specific oral anticoagulant-associated bleeding. Blood, 2014, 123, 1152-1158.	1.4	108
95	Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S18-S21.	3.4	39
96	Acute management of bleeding in patients on novel oral anticoagulants. European Heart Journal, 2013, 34, 489-498.	2.2	152
97	Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis, 2013, 35, 391-398.	2.1	78
98	Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. Circulation, 2012, 126, 1630-1639.	1.6	406
99	Acute Hepatic Necrosis and Ischemic Limb Necrosis. New England Journal of Medicine, 2012, 367, 879-881.	27.0	21
100	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. Blood, 2011, 118, 545-545.	1.4	1
101	Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review. American Journal of Kidney Diseases, 2010, 56, 1140-1157.	1.9	23
102	Type II Bidirectional Ventricular Tachycardia as a Mechanism of Termination of Sustained Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology, 2009, 20, 345-346.	1.7	7
103	Complete heart block following intentional carbamate ingestion. Canadian Journal of Cardiology, 2009, 25, e288-e290.	1.7	8
104	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Adult Liver Transplant Recipients. Clinical Infectious Diseases, 2008, 47, 885-892.	5.8	67
105	A Randomized, Double-Blind Trial of Pneumococcal Vaccination in Adult Allogeneic Stem Cell Transplant Donors and Recipients. Clinical Infectious Diseases, 2007, 45, 1576-1582.	5.8	74
106	Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance. Biology of Blood and Marrow Transplantation, 2007, 13, 1369-1379.	2.0	143
107	A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients. American Journal of Transplantation, 2005, 5, 1462-1468.	4.7	89
108	Clinical Impact of Community-Acquired Respiratory Viruses on Bronchiolitis Obliterans After Lung Transplant. American Journal of Transplantation, 2005, 5, 2031-2036.	4.7	249

#	ARTICLE	IF	CITATIONS
109	A Prospective Assessment of Valganciclovir for the Treatment of Cytomegalovirus Infection and Disease in Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2005, 192, 1154-1157.	4.0	46
110	Brain vesicular acetylcholine transporter in human users of drugs of abuse. <i>Synapse</i> , 2004, 52, 223-232.	1.2	22